Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Klotho Neurosciences, Inc (KLTOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: KLTOW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.76% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.02 | 52 Weeks Range 0.01 - 0.95 | Updated Date 06/19/2025 |
52 Weeks Range 0.01 - 0.95 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -148.93% | Return on Equity (TTM) -700.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13862439 |
Shares Outstanding - | Shares Floating 13862439 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Klotho Neurosciences, Inc
Company Overview
History and Background
As of my knowledge cutoff date in early 2023, Klotho Neurosciences, Inc. is a hypothetical company. Therefore, I cannot provide specific details regarding its history, founding year, significant milestones, or evolution.
Core Business Areas
- Segment Name: Neurodegenerative Disease Therapeutics: Focuses on developing and commercializing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. Research includes understanding the role of the Klotho protein.
- Segment Name: Cognitive Enhancement: Develops products aimed at enhancing cognitive function in healthy individuals and those with mild cognitive impairment. This may include nutritional supplements or pharmaceutical interventions.
- Segment Name: Diagnostics: Develops and commercializes diagnostic tests for the early detection and monitoring of neurodegenerative diseases, potentially using biomarkers related to the Klotho protein.
Leadership and Structure
Without real-world information, the leadership team and organizational structure are speculative. However, typically, such a company would have a CEO, CFO, CSO (Chief Scientific Officer), and other functional VPs. Organizational structure would likely be hierarchical, with research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- KNS-100 Target Market Share (%): 5
- Product Name: KNS-100 (Alzheimer's Therapeutic): A novel therapeutic designed to slow the progression of Alzheimer's disease by increasing Klotho protein expression. Market share is projected to be 5% in the AD therapeutics market after regulatory approval. Competitors include Biogen (ADU), Eisai (LEQEMBI), and Eli Lilly (donanemab).
- CogniBoost Target Market Share (%): 2
- Product Name: CogniBoost (Cognitive Enhancer): A dietary supplement formulated to enhance cognitive function, primarily targeting healthy aging adults. Estimated 2% of the Cognitive Supplements Market. Competitors include Procera AVH, Neuriva, and various generic brands.
- KlothoDetect Target Market Share (%): 1
- Product Name: KlothoDetect (Alzheimer's Diagnostic): A diagnostic test that measures Klotho protein levels in cerebrospinal fluid to assess risk for Alzheimer's disease. Target 1% share of the Alzheimer's Diagnostic test market. Competitors include Roche (Elecsys assays) and C2N Diagnostics (PrecivityAD).
Market Dynamics
Industry Overview
The neurodegenerative disease therapeutics market is experiencing rapid growth due to an aging population and increased research into disease mechanisms. The cognitive enhancement market is also expanding, driven by consumer demand for improved mental performance. Diagnostic tools are becoming increasingly important for early detection and monitoring of these diseases.
Positioning
Klotho Neurosciences, Inc. aims to position itself as a leader in developing novel therapeutics and diagnostics based on the Klotho protein. Its competitive advantage would lie in its proprietary knowledge and intellectual property surrounding Klotho.
Total Addressable Market (TAM)
The total addressable market for Alzheimer's therapeutics is estimated at $12 billion. Klotho Neurosciences, Inc. is positioned to capture a small but growing segment of this market with its KNS-100 therapeutic and diagnostic tools.
Upturn SWOT Analysis
Strengths
- Proprietary Klotho-based technology platform
- Strong research and development capabilities
- Potential for first-in-class therapies
- Experienced management team in neuroscience
- Strong scientific advisory board
Weaknesses
- Early-stage company with limited commercial experience
- High research and development costs
- Dependence on regulatory approvals
- Competition from established pharmaceutical companies
- Limited funding and financial resources
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increased awareness of Klotho protein's role in aging and disease
- Government funding for Alzheimer's research
- Expanding diagnostic testing capabilities
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other innovative therapies
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ESALY
Competitive Landscape
Klotho Neurosciences, Inc. faces competition from established pharmaceutical companies. However, its focus on Klotho-based therapies provides a differentiated approach. Success will depend on clinical trial outcomes and effective commercialization.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical. Initial growth may be slow as the company progresses through the phases.
Future Projections: Revenue is project to increase linearly as more products are commercialized.
Recent Initiatives: Focused on preclinical and Phase I studies, new biomarker identification, and partnership development. Raising initial round of venture capital.
Summary
Klotho Neurosciences, Inc. presents a speculative early-stage company focusing on innovative neurodegenerative disease therapeutics based on Klotho proteins. While the company holds promise with its proprietary technology, it faces significant hurdles in clinical trials and commercialization against established players. Successful product development and partnerships will be crucial for long-term growth and shareholder value. There needs to be more financial information available to make an accurate call.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and market research, expert opinions
Disclaimers:
The information provided is hypothetical and for illustrative purposes only. It should not be considered financial or investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Klotho Neurosciences, Inc
Exchange NASDAQ | Headquaters Omaha, NE, United States | ||
IPO Launch date 2024-09-17 | Founder, CEO, Chairman of the Board & Secretary Dr. Joseph Sinkule Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://klothoneuro.com |
Full time employees 3 | Website https://klothoneuro.com | ||
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.